[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE0302756D0 - Novel Compounds - Google Patents

Novel Compounds

Info

Publication number
SE0302756D0
SE0302756D0 SE0302756A SE0302756A SE0302756D0 SE 0302756 D0 SE0302756 D0 SE 0302756D0 SE 0302756 A SE0302756 A SE 0302756A SE 0302756 A SE0302756 A SE 0302756A SE 0302756 D0 SE0302756 D0 SE 0302756D0
Authority
SE
Sweden
Prior art keywords
sup
novel compounds
compounds
prophylaxis
inhibitors
Prior art date
Application number
SE0302756A
Other languages
English (en)
Inventor
Anthony Kettle
Anna-Karin Tiden
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0302756A priority Critical patent/SE0302756D0/sv
Publication of SE0302756D0 publication Critical patent/SE0302756D0/sv
Priority to US10/575,592 priority patent/US20070032468A1/en
Priority to PCT/SE2004/001477 priority patent/WO2005037835A1/en
Priority to JP2006535309A priority patent/JP2007508373A/ja
Priority to EP04775551A priority patent/EP1678179A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0302756A 2003-10-17 2003-10-17 Novel Compounds SE0302756D0 (sv)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE0302756A SE0302756D0 (sv) 2003-10-17 2003-10-17 Novel Compounds
US10/575,592 US20070032468A1 (en) 2003-10-17 2004-10-14 Novel thioxanthine derivatives for use as inhibitors of mpo
PCT/SE2004/001477 WO2005037835A1 (en) 2003-10-17 2004-10-14 Novel thioxanthine derivatives for use as inhibitors of mpo
JP2006535309A JP2007508373A (ja) 2003-10-17 2004-10-14 新規な化合物
EP04775551A EP1678179A1 (en) 2003-10-17 2004-10-14 Novel thioxanthine derivatives for use as inhibitors of mpo

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302756A SE0302756D0 (sv) 2003-10-17 2003-10-17 Novel Compounds

Publications (1)

Publication Number Publication Date
SE0302756D0 true SE0302756D0 (sv) 2003-10-17

Family

ID=29398764

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0302756A SE0302756D0 (sv) 2003-10-17 2003-10-17 Novel Compounds

Country Status (5)

Country Link
US (1) US20070032468A1 (sv)
EP (1) EP1678179A1 (sv)
JP (1) JP2007508373A (sv)
SE (1) SE0302756D0 (sv)
WO (1) WO2005037835A1 (sv)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0402591D0 (sv) * 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
AU2006322349A1 (en) * 2005-12-07 2007-06-14 Ucb Pharma, S.A. Xanthine derivatives, processes for preparing them and their uses
US20090286813A1 (en) * 2006-04-13 2009-11-19 Astrazeneca Ab Thioxanthine Derivatives and Their Use as Inhibitors of MPO
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
JP2009539829A (ja) * 2006-06-05 2009-11-19 アストラゼネカ・アクチエボラーグ ミエロペルオキシダーゼ阻害剤としてのピロロ［３，２−ｄ］ピリミジン−４−オン誘導体
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090053176A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Combination 937
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
WO2010068171A1 (en) * 2008-12-12 2010-06-17 Astrazeneca Ab A process for the preparation of 3- [ (2r) tetrahydrofuran-2- ylmethyl] -2-thioxo-l, 2, 3, 7-tetrahydro-6h-purin-6-one
WO2011133581A1 (en) 2010-04-19 2011-10-27 General Atomics Methods and compositions for assaying enzymatic activity of myeloperoxidase in blood samples
US9616063B2 (en) 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
AR130237A1 (es) 2022-08-18 2024-11-20 Astrazeneca Ab Inhibidores de mieloperoxidasa

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135753A (en) * 1961-05-10 1964-06-02 Burroughs Wellcome Co Alkylthiopurines and method
US4710503A (en) * 1985-02-07 1987-12-01 Euroceltique S.A. 6-thioxanthine derivatives
GB8918297D0 (en) * 1989-08-10 1989-09-20 Beecham Group Plc Novel treatment
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
US6046019A (en) * 1991-07-09 2000-04-04 Goumeniouk; Alexander P. Diagnostic kits and methods for making granulocyte cell counts
HUT76784A (en) * 1993-11-26 1997-11-28 Pfizer Antiinflammatory isoxazoline compounds and pharmaceutical compositions containing them
US5489598A (en) * 1994-06-08 1996-02-06 Warner-Lambert Company Cytoprotection utilizing aryltriazol-3-thiones
ATE247116T1 (de) * 1994-12-13 2003-08-15 Euro Celtique Sa Arylthioxanthine
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
WO1996018400A1 (en) * 1994-12-13 1996-06-20 Euro-Celtique, S.A. Trisubstituted thioxanthines
EP0799040B1 (en) * 1994-12-13 2003-08-20 Euroceltique S.A. Trisubstituted thioxanthines
US5756511A (en) * 1995-04-03 1998-05-26 Cell Therapeutics, Inc. Method for treating symptoms of a neurodegenerative condition
US6294541B1 (en) * 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
US5976823A (en) * 1997-03-19 1999-11-02 Integrated Biomedical Technology, Inc. Low range total available chlorine test strip
US6319928B1 (en) * 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
BR0011182A (pt) * 1999-04-02 2003-06-10 Euro Celtique Sa Derivados de purina tendo atividade inibidora de fosfodiesterase iv
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
US6855817B2 (en) * 2000-07-21 2005-02-15 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
FR2819723B1 (fr) * 2001-01-23 2006-11-17 Arnaud Mainnemare Composition halogene, son procede de preparation et ses utilisations
SE0103766D0 (sv) * 2001-11-09 2001-11-09 Astrazeneca Ab Novel assay
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
JP5274455B2 (ja) * 2006-06-23 2013-08-28 インサイト コーポレイション Ｈｍ７４ａアゴニストとしてのプリノン誘導体
TWI423977B (zh) * 2006-06-23 2014-01-21 Incyte Corp 作為ｈｍ７４ａ同效劑之嘌呤酮衍生物（一）

Also Published As

Publication number Publication date
EP1678179A1 (en) 2006-07-12
US20070032468A1 (en) 2007-02-08
WO2005037835A1 (en) 2005-04-28
JP2007508373A (ja) 2007-04-05

Similar Documents

Publication Publication Date Title
TW200626601A (en) Novel compounds
SE0202463D0 (sv) Novel compounds
SE0302487D0 (sv) Novel compounds
HK1089163A1 (en) Quinoxaline derivatives as neutrophil elastase inhibitors and their use
MX2007009372A (es) Nuevos compuestos ii derivados de 2-piridina como inhibidores de elastasa neutrofila.
ZA200306419B (en) Phenyl derivatives.
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
MXPA03010142A (es) Nuevos derivados de arilheteroalquilamina.
SE0302323D0 (sv) Novel compounds
SE0302756D0 (sv) Novel Compounds
SE9803518D0 (sv) Novel compounds
AU2003278667A1 (en) Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
SE9803773D0 (sv) Compounds
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
SE0202461D0 (sv) Novel compounds
SE0102641D0 (sv) Novel compounds
AU2001234314A1 (en) Novel phenylheteroalkylamine derivatives
SE0102639D0 (sv) Novel compounds
SE0102640D0 (sv) Novel compounds
SE9904676D0 (sv) Novel compounds
SE0103325D0 (sv) Novel compounds
SE0202280D0 (sv) Novel compounds
SE9901901D0 (sv) Compounds